Inteum Company
Links
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - schizophrenia
5
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
A CSF-derived therapy for psychiatric disorders
NU2023-196 INVENTORS Peter Penzes* Marc Dos Santos BACKGROUND Currently, there is a lack of treatments which address the negative and cognitive symptoms of psychiatric disorders such as
schizophrenia
. Northwestern researchers have designed a recombinant form of ⍺2d-1 protein, a subunit of the voltage-gated calcium channel, to restore protein...
Published: 12/23/2025
|
Inventor(s):
Keywords(s):
Biologic
,
Neurologic disease
,
Neurology
,
PSD - Psychotic spectrum disorder
,
Psychiatric disease
,
Schizophrenia
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Methods of making and using dopamine receptor selective antagonists/partial agonists
Abstract: Dopamine is a major neurotransmitter in the central nervous system and among other functions is directly related to the rewarding effects of drugs of abuse. Dopamine signaling is mediated by D1, D2, D3, D4 and D5 receptors. The dopamine D3 receptor is a known target to treat a variety of neuropsychiatric disorders, including substance use...
Published: 4/22/2025
|
Inventor(s):
Amy Newman
,
Vivek Kumar
,
Anverbasha Shaik
Keywords(s):
Bipolar Disorder
,
Cannabis
,
DEPENDENCE
,
dopamine D3 receptor
,
drug addiction
,
oxycodone
,
SCHIZOPHRENIA
Category(s):
Collaboration Sought > Collaboration
,
Collaboration Sought > Licensing
,
TherapeuticArea > Neurology
,
Application > Therapeutics
Repurposing Bumetanide to Address Cognitive Deficits in
Schizophrenia
NU 2019-067 INVENTORS Herbert Y. Meltzer SHORT DESCRIPTION Repurposing bumetaide to treat cognitive deficits in
schizophrenia
syndrome. ABSTRACT Cognitive deficits associated with schizophrenia syndrome are the components that contribute most to a low quality of life. While current pharmacological treatments have beneficial effects on treating...
Published: 12/16/2025
|
Inventor(s):
Keywords(s):
Neurologic disease
,
Neurology
,
PSD - Psychotic spectrum disorder
,
Repurposed Drugs
,
Schizophrenia
,
Small molecule
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
A Mouse Model for Mental Disorders and Epilepsy
Current State of the Art The Neuregulin/ErbB4 signaling pathway is involved in GABAergic neurotransmission, an important inhibitory neurotransmission that regulates several processes in the central nervous system including muscle tone. Aberrant GABAergic function has been implicated in
Schizophrenia
, Schizo-affective disorder and in Epilepsy....
Published: 4/29/2020
|
Inventor(s):
Lin Mei
,
Wen-Cheng Xiong
Keywords(s):
Drug Discovery
,
Drug Testing
,
Epilepsy
,
Mouse
,
Schizophrenia
Category(s):
Research Tools
Therapeutic Compounds to Enhance Cognition, Counteract Depression and Treat Smoking Addiction
Chemicals Selectively Modulate Cell Receptors Linked to Neurological Disorders in Humans and Other MammalsThese compounds enable effective treatment of neurological disorders involving cognitive deficits (including Alzheimer’s and Parkinson’s diseases), depression and drug dependences such as tobacco (nicotine) and betel nut addictions....
Published: 6/27/2021
|
Inventor(s):
William Kem
,
Ferenc Soti
,
Hong Xing
Keywords(s):
Alzheimer's Disease
,
Anti-Inflammatory
,
Cognition Enhancer
,
Dementia
,
Parkinson's Disease
,
Post Traumatic Stress Disorder
,
Schizophrenia
,
Wound Healing
Category(s):
Technology Classifications > Human Health Care > Therapeutics